Table 1 Demographics, clinical and surgical characteristics of the women versus men in the cohort before propensity score matching

Age (years)

71.2 ± 11.7

61.8 ± 13.4

69.3 ± 9.9

65.2 ± 11.7

Comorbid conditions

 Diabetes mellitus

7374 (54.6%)

15,866 (34.0%)

1212 (68.8%)

2644 (47.5%)

 Hypertension

10,448 (77.3%)

27,716 (59.4%)

1420 (80.6%)

3734 (67.1%)

 Dyslipidemia

5901 (43.7%)

21,987 (47.1%)

681 (38.6%)

1942 (34.9%)

 Heart failure hospitalization

1647 (12.2%)

2041 (4.4%)

265 (15.0%)

435 (7.8%)

 Peripheral arterial disease

807 (6.0%)

1412 (3.0%)

137 (7.8%)

339 (6.1%)

 Prior stroke hospitalization

2550 (18.9%)

4998 (10.7%)

353 (20.0%)

901 (16.2%)

 COPD

945 (7.0%)

4203 (9.0%)

111 (6.3%)

678 (12.2%)

 Liver cirrhosis

245 (1.8%)

905 (1.9%)

19 (1.1%)

122 (2.2%)

 Malignancy

773 (5.7%)

1860 (4.0%)

60 (3.4%)

177 (3.2%)

 Autoimmune disease

434 (3.2%)

552 (1.2%)

43 (2.4%)

65 (1.2%)

 Chronic kidney disease

3689 (27.3%)

7024 (15.0%)

598 (33.9%)

1480 (26.6%)

 Dialysis

980 (7.3%)

1371 (2.9%)

115 (6.5%)

240 (4.3%)

Charlson’s Comorbidity Index score

3.4 ± 2.1

2.5 ± 1.8

3.8 ± 2.0

3.1 ± 2.0

Bleeding history

 Major bleeding

964 (7.1%)

2180 (4.7%)

94 (5.3%)

247 (4.4%)

 GI bleeding

2758 (20.4%)

5721 (12.3%)

305 (17.3%)

734 (13.2%)

 ICH

200 (1.5%)

548 (1.2%)

22 (1.2%)

56 (1.0%)

 Anemia

506 (3.7%)

608 (1.3%)

49 (2.8%)

73 (1.3%)

Hospital level

 Medical center (teaching hospital)

6454 (47.8%)

23,883 (51.1%)

1185 (67.3%)

3762 (67.6%)

 Regional/district hospital

7060 (52.2%)

22,810 (48.9%)

577 (32.7%)

1803 (32.4%)

Type of CABG

 On pump

–

–

1447 (82.1%)

4577 (82.2%)

 Off pump

–

–

315 (17.9%)

988 (17.8%)

Endarterectomy

79 (4.5%)

274 (4.9%)

Concomitant valve surgery

–

–

136 (7.7%)

316 (5.7%)

Valve location and type

 Aortic valve replacement

–

–

48 (2.7%)

131 (2.4%)

 Mitral valve repair

–

–

30 (1.7%)

80 (1.4%)

 Mitral valve replacement

–

–

60 (3.4%)

123 (2.2%)

Details of coronary stenting

 Type of stent

  BMS

10,076 (74.6%)

34,400 (73.7%)

–

–

  DES

3438 (25.4%)

12,293 (26.3%)

–

–

 Number of stenting

1.03 ± 0.17

1.03 ± 0.16

–

–

Number of intervened/grafted vessels

 1

10,118 (74.9%)

37,482 (80.3%)

134 (7.6%)

298 (5.4%)

 2

2984 (22.1%)

8201 (17.6%)

339 (19.2%)

911 (16.4%)

 3

412 (3.0%)

1010 (2.2%)

1289 (73.2%)

4356 (78.3%)

Antiplatelet therapy at discharge

 Aspirin

9675 (71.6%)

38,780 (83.1%)

665 (37.7%)

2597 (46.7%)

 Clopidogrel/ticlopidine

11,027 (81.6%)

41,574 (89.0%)

425 (24.1%)

1496 (26.9%)

 Antiplatelet therapy

  Single

4089 (30.3%)

8675 (18.6%)

1686 (95.7%)

5204 (93.5%)

  Dual

9425 (69.7%)

38,018 (81.4%)

76 (4.3%)

361 (6.5%)

Other medications at discharge

 Statin

6357 (47.0%)

26,159 (56.0%)

431 (24.5%)

1447 (26.0%)

 Beta-blocker

6909 (51.1%)

26,955 (57.7%)

563 (32.0%)

1934 (34.8%)

 ACEI/ARB

7683 (56.9%)

28,702 (61.5%)

528 (30.0%)

1492 (26.8%)

 OAC drugs

203 (1.5%)

792 (1.7%)

59 (3.3%)

251 (4.5%)

 OHA drugs

4457 (33.0%)

10,819 (23.2%)

604 (34.3%)

1557 (28.0%)

 Insulin

1333 (9.9%)

1753 (3.8%)

283 (16.1%)

437 (7.9%)

 PPI

901 (6.7%)

2233 (4.8%)

111 (6.3%)

299 (5.4%)

 NSAID

2763 (20.4%)

9253 (19.8%)

284 (16.1%)

1029 (18.5%)

Follow-up (years)

2.8 ± 2.7

3.4 ± 2.8

3.2 ± 3.4

3.8 ± 3.6